Market Trends of China Drug Delivery Devices Industry
Auto-Injectors Segment is Expected to Hold the Significant Market Share During the Forecast Period
- The auto-injectors segment is expected to witness significant growth due to collaborations and partnerships among companies for auto-injectors, convenient usage, and the increased burden of chronic diseases. For instance, according to the report published by the National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID) in October 2021, there will be about 5 million rheumatoid arthritis patients in China 2021, with an average onset age of 45 years.
- Hence, for treating chronic diseases, there is a need for self-injectable devices like auto-injectors, which are convenient and easy to use. Thus, the segment drives the growth of the market during the study period.
- The product launches by the market players are expected to propel the growth of the market over the forecast period. For instance, in July 2021, ALK Abello and China Grand Pharma entered an exclusive licensing agreement for adrenaline autoinjector ALK's AAI Jext to launch the product in China.
- Thus, due to the above-mentioned factors, such as the growing burden of chronic diseases and product approvals, the auto-injectors segment is expected to grow significantly during the forecast period.
Pulmonary Disease Segment is Expected to Hold the Significant Market Share During the Forecast Period
Pulmonary disease is a type of disease that affects the lungs and other parts of the respiratory system. Pulmonary diseases may be caused by infection, by smoking tobacco, or by breathing in second-hand tobacco smoke, radon, asbestos, or other forms of air pollution. Some of the most common pulmonary diseases are chronic obstructive pulmonary disease (COPD), asthma, occupational lung diseases, and pulmonary hypertension. The pulmonary drug devices help to inhale through the mouth and deposit in the lower airways. The pulmonary diseases segment is expected to hold a significant market share owing to the rise in prevalence of this disease in the country and demand for the drug-delivery devices.
According to the study published in the Value in Health Regional Issues in November 2022, between 2020 and 2039, it was expected that China would experience a rise in the number of COPD patients from 88.3 million to 103.3 million; this increase would be accompanied by a 31% rise in the number of severe cases. Thus, the significant burden of COPD in the country is expected to propel the growth of the segment over the forecast period.
The technological advancements in drug delivery technology have increased the demand for the management of diseases and, hence, are expected to boost segment growth. According to the study published in the Journal of Bio Integration in November 2021, the use of nano-based delivery systems for pulmonary drug delivery, such as liposomes, micelles, and nanoparticles, has proven to be a successful method for achieving drug deposition and sustained controlled drug release in the lungs. The application of nanotechnology continues to offer several benefits in the treatment of various chronic diseases, such as pulmonary disease, and results in remarkable improvements in treatment outcomes. The study was conducted in China, and the adoption of this technology in drug delivery devices may propel the demand for drug delivery devices over the forecast period. Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
